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1. INTRODUCTION {#edm216-sec-0005}
===============

It is well documented that the higher the baseline HbA~1c~, the greater the decline in HbA~1c~ when oral antidiabetes agents are given to patients with type 2 diabetes.[1](#edm216-bib-0001){ref-type="ref"}, [2](#edm216-bib-0002){ref-type="ref"}, [3](#edm216-bib-0003){ref-type="ref"}, [4](#edm216-bib-0004){ref-type="ref"} In patients with type 2 diabetes treated with an oral antidiabetes agent for ≥12 weeks, a 0.2%‐0.5% greater decrement in HbA~1c~ has been reported for every 1% higher baseline HbA~1c~.[1](#edm216-bib-0001){ref-type="ref"} In a meta‐regression analysis of randomized controlled trials, treatment with dipeptidyl peptidase‐4 (DPP4) inhibitors for ≥12 weeks led to a ≥ 0.26% greater reduction in HbA~1c~ for every percentage point of baseline HbA~1c~ \>7%.[2](#edm216-bib-0002){ref-type="ref"} The universality of these findings suggests a nonspecific mechanism. This mechanism has yet to be determined, but could be related to on‐treatment improvements in beta‐cell or alpha‐cell functions.[5](#edm216-bib-0005){ref-type="ref"}, [6](#edm216-bib-0006){ref-type="ref"}

Sodium‐glucose cotransporter 2 (SGLT2) inhibitors inhibit sodium‐glucose cotransport in the proximal tubule. This reduces the blood glucose level at which the capacity for glucose transport by SGLTs is saturated, and therefore, the blood glucose level at which glucose is spilled into the urine---also referred to as the renal threshold for glucose.[7](#edm216-bib-0007){ref-type="ref"} By lowering the renal threshold for glucose, glucose that would otherwise be reabsorbed in the kidney is excreted into the urine. The constitutive renal threshold for plasma glucose in patients with type 2 diabetes is typically in the range of \~10‐11 mmol/L (180‐200 mg/dL) without SGLT2 inhibitor treatment.[8](#edm216-bib-0008){ref-type="ref"} The amount of filtered glucose in the kidney is dependent on glomerular filtration rate (GFR) and blood glucose. Therefore, the amount of reabsorbed glucose increases linearly with blood glucose (for a given GFR) until the renal threshold for glucose is reached; with higher glucose levels, the reabsorbed glucose stays constant except for a minor splay between the two parts of the absorption curve.[9](#edm216-bib-0009){ref-type="ref"}, [10](#edm216-bib-0010){ref-type="ref"} Glucose lowering with SGLT2 inhibitors is expected to increase linearly with increasing blood glucose up to approximately 10‐11 mmol/L (representing the renal threshold for glucose in the untreated situation). This effect of SGLT2 inhibitors could differ from, and could possibly be in addition to, a nonspecific increase in glucose lowering with increasing blood glucose common to any glucose‐lowering intervention. No study has compared the slope of the decrement in HbA~1c~ in relation to baseline HbA~1c~ with an SGLT2 inhibitor vs other oral antidiabetes agents.

Empagliflozin is a potent and selective inhibitor of SGLT2.[11](#edm216-bib-0011){ref-type="ref"} In Phase III trials in patients with type 2 diabetes, empagliflozin 10 mg/d and 25 mg/d as monotherapy or as add‐on therapy significantly reduced HbA~1c~ compared with placebo after 24 weeks of treatment.[12](#edm216-bib-0012){ref-type="ref"}, [13](#edm216-bib-0013){ref-type="ref"}, [14](#edm216-bib-0014){ref-type="ref"}, [15](#edm216-bib-0015){ref-type="ref"} The reduction in HbA~1c~ with empagliflozin monotherapy was significantly greater in patients with baseline HbA~1c~ ≥8.5% compared with patients with baseline HbA~1c~ \<8.5%.[12](#edm216-bib-0012){ref-type="ref"}

We hypothesized that with increasing baseline HbA~1c~ up to \~ 11% (ie, with a large proportion of blood glucose below the untreated renal threshold for glucose), empagliflozin would produce a greater HbA~1c~ reduction in patients with type 2 diabetes compared with antidiabetes agents with other mechanisms of action. To test this hypothesis, we compared the slopes of regression in HbA~1c~ with empagliflozin vs with sitagliptin or glimepiride using data from two randomized controlled trials in patients with type 2 diabetes. A major advantage of this analysis compared with previous analyses with other oral antidiabetes agents is the use of individual patient data as opposed to mean data.

2. METHODS {#edm216-sec-0006}
==========

2.1. Patients and study designs {#edm216-sec-0007}
-------------------------------

Study 1 (EMPA‐REG MONO™) was a Phase III, double‐blind, active‐ and placebo‐controlled trial. Drug‐naïve patients with type 2 diabetes (no oral or injected antidiabetes medication for ≥12 weeks prior to randomization), aged ≥18 years, with body mass index (BMI) ≤45 kg/m^2^ and HbA~1c~ ≥7% to ≤10%, were randomized to receive empagliflozin 10 mg/d, empagliflozin 25 mg/d, sitagliptin 100 mg/d or placebo for 24 weeks. The primary end‐point was change from baseline in HbA~1c~ at week 24.[12](#edm216-bib-0012){ref-type="ref"}

Study 2 (EMPA‐REG H2H‐SU™) was a Phase III, double‐blind, active‐controlled trial. Metformin (immediate release, IR)‐treated patients with type 2 diabetes, aged ≥18 years, with BMI ≤45 kg/m^2^ and HbA~1c~ ≥7% to ≤10% were randomized to receive empagliflozin 25 mg/d or glimepiride 1‐4 mg/d as add‐on to metformin for 104 weeks. Patients were required to be on an unchanged dose of metformin IR (≥1500 mg/d, maximum tolerated dose or maximum dose according to the local label) for ≥12 weeks prior to randomization. Glimepiride was initiated at a dose of 1 mg/d, with a recommendation for uptitration if fasting plasma glucose was \>6.1 mmol/L to 2 mg/d at week 4, 3 mg/d at week 8 and 4 mg/d at week 12. The mean ± SD maximum titrated glimepiride dose was 2.71 ± 1.24 mg/d. The primary end‐point was change from baseline in HbA~1c~ at week 52 and week 104.[16](#edm216-bib-0016){ref-type="ref"}

2.2. Statistical analyses {#edm216-sec-0008}
-------------------------

To compare the decline in HbA~1c~ with empagliflozin 10 mg and 25 mg vs sitagliptin after 24 weeks (Study 1) and with empagliflozin 25 mg vs glimepiride after 52 weeks and 104 weeks (Study 2), the least squares (LS) mean change from baseline in HbA~1c~ in each study was analysed using a mixed model for repeated measurements (MMRMs). The model included the fixed categorical effects of treatment, visit and treatment‐by‐visit interaction, as well as the continuous, fixed covariates of baseline, baseline‐by‐treatment, baseline‐by‐visit interaction and baseline‐by‐treatment‐by‐visit interaction. An unstructured covariance model was used to model the within‐patient measurements. This model allowed estimation of the treatment‐specific slope (ie, the magnitude of change in HbA~1c~ for a unit change in baseline HbA~1c~) and its 95% confidence interval (CI) for the regression of change from baseline in HbA~1c~ on the baseline HbA~1c~. *P*‐values for the test of a difference of the slopes between treatment groups were calculated. Regression lines from scatter plots were estimated from a simple linear model within each treatment group, for which the change from baseline at the week of interest was calculated as the intercept + baseline HbA~1c~\*slope. Thus, the difference between the slopes and the regression lines in the scatter plots was analysed using different models; slope values from both approaches are reported. Analyses were conducted in all patients who received ≥1 dose of study medication and who had a baseline HbA~1c~ measurement. HbA~1c~ values are presented as %. The following formula can be used to convert values to mmol/mol: \[HbA~1c~ (%) ‐ 2.15\] × 10.929.

3. RESULTS {#edm216-sec-0009}
==========

3.1. Study 1 {#edm216-sec-0010}
------------

Baseline patient characteristics were similar between the empagliflozin and sitagliptin groups (Table [1](#edm216-tbl-0001){ref-type="table"}). LS mean reductions in HbA~1c~ at week 24 by baseline HbA~1c~ are shown in Figure [1](#edm216-fig-0001){ref-type="fig"}. A steeper slope of HbA~1c~ reduction was observed with empagliflozin 10 mg or 25 mg compared with sitagliptin. The regression analysis showed slopes of −0.59 (95% CI: −0.70, −0.47), −0.49 (95% CI −0.62, −0.37) and −0.29 (95% CI −0.42, −0.14) for empagliflozin 10 mg, empagliflozin 25 mg and sitagliptin, respectively. The slope was significantly different for both empagliflozin 10 mg (*P* \< .001) and empagliflozin 25 mg (*P* = .023) compared with sitagliptin. There was no significant difference between the slopes for empagliflozin 10 mg vs empagliflozin 25 mg. Scatter plots of change from baseline in HbA~1c~ at week 24 by baseline HbA~1c~ are shown in Figure [S1](#edm216-sup-0001){ref-type="supplementary-material"}. The conclusions from slopes derived from regression lines of the scatter plots were similar to those from the LS means slope analyses (Figure [S1](#edm216-sup-0001){ref-type="supplementary-material"}).

###### 

Baseline characteristics

                                                       Study 1        Study 2                                      
  ---------------------------------------------------- -------------- -------------- -------------- -------------- --------------
  Male, n (%)                                          142 (63)       145 (65)       141 (63)       432 (56)       421 (54)
  Race, n (%)                                                                                                      
  Asian                                                143 (64)       144 (64)       143 (64)       254 (33)       253 (32)
  White                                                77 (34)        73 (33)        76 (34)        498 (65)       519 (67)
  Other                                                4 (2)          7 (3)          4 (2)          13 (2)         8 (1)
  Age, years                                           56.2 ± 11.6    53.8 ± 11.6    55.1 ± 9.9     56.2 ± 10.3    55.7 ± 10.4
  Time (y) since diagnosis of type 2 diabetes, n (%)                                                               
  ≤1                                                   87 (39)        91 (41)        93 (42)        79 (10)        93 (1.2)
  \>1 to 5                                             92 (41)        83 (37)        86 (39)        341 (45)       336 (43)
  \>5                                                  45 (20)        50 (22)        44 (20)        345 (45)       351 (45)
  Body weight, kg                                      78.4 ± 18.7    77.8 ± 18.0    79.3 ± 20.4    82.5 ± 19.2    83.0 ± 19.2
  eGFR, mL/min/1.73 m^2^,                              87.7 ± 19.2    87.6 ± 18.3    87.6 ± 17.3    88.2 ± 18.9    88.2 ± 17.8
  HbA~1c~, %                                           7.87 ± 0.88    7.86 ± 0.85    7.85 ± 0.79    7.92 ± 0.81    7.92 ± 0.86
  SBP, mm Hg                                           133.0 ± 16.6   129.9 ± 17.5   132.5 ± 15.8   133.4 ± 15.9   133.5 ± 16.0
  DBP, mm Hg                                           79.2 ± 9.6     78.3 ± 9.4     80.1 ± 10.0    79.5 ± 9.6     79.4 ± 9.2

Values are mean ± SD, unless otherwise stated, in all patients who received ≥1 dose of study medication and who had a baseline HbA~1c~ measurement.

DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate by Modification of Diet and Renal Disease (MDRD) equation; HbA~1c~, glycated haemoglobin; SBP, systolic blood pressure.
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![LS mean change in HbA~1c~ by baseline HbA~1c~ with empagliflozin 10 mg and 25 mg and sitagliptin monotherapy after 24 wk analysed using a mixed model for repeated measurements. HbA~1c~---glycated haemoglobin](EDM2-1-e00016-g001){#edm216-fig-0001}

3.2. Study 2 {#edm216-sec-0011}
------------

Baseline patient characteristics were similar between the empagliflozin and glimepiride groups (Table [1](#edm216-tbl-0001){ref-type="table"}). LS mean reductions in HbA~1c~ at week 52 and week 104 by baseline HbA~1c~ are shown in Figure [2](#edm216-fig-0002){ref-type="fig"}. Steeper slopes of HbA~1c~ reduction were observed with empagliflozin 25 mg than with glimepiride. The regression analysis showed slopes of −0.52 (95% CI −0.59, −0.44) and −0.32 (95% CI −0.39, −0.25) for empagliflozin 25 mg and glimepiride, respectively, at week 52 and −0.48 (95% CI −0.56, −0.40) and −0.37 (95% CI −0.45, −0.28) for empagliflozin 25 mg and glimepiride, respectively, at week 104. The slopes were steeper for empagliflozin 25 mg compared with glimepiride, reaching significance at week 52 (*P* \< .001), and were of borderline significance at week 104 (*P* = .07). The slopes relating to the reduction in HbA~1c~ as a function of time for empagliflozin‐treated patients in this study were very similar to the slope for empagliflozin 25 mg in Study 1. Scatter plots of change from baseline in HbA~1c~ at weeks 52 and 104 by baseline HbA~1c~ are shown in Figure [S2](#edm216-sup-0001){ref-type="supplementary-material"}. The conclusions from slopes derived from regression lines of the scatter plots were similar to those from the LS means slope analyses (Figure [S2](#edm216-sup-0001){ref-type="supplementary-material"}).
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4. DISCUSSION {#edm216-sec-0012}
=============

We analysed the effect of baseline HbA~1c~ on the slope of HbA~1c~ reduction with empagliflozin compared with two other commonly used antidiabetes agents (sitagliptin and glimepiride) using individual patient data from two randomized controlled trials.[12](#edm216-bib-0012){ref-type="ref"}, [16](#edm216-bib-0016){ref-type="ref"} Our findings demonstrate that the decrement in HbA~1c~ by baseline HbA~1c~, as reflected by the slope of HbA~1c~ reduction, was greater with empagliflozin compared to both sitagliptin and glimepiride in patients with type 2 diabetes. The similar slopes of regression in HbA~1c~ with empagliflozin 25 mg in Studies 1 and 2 emphasize the reproducibility of the empagliflozin results. Based on the results of Study 1, it can be predicted that for a starting HbA~1c~ of 10.0%, 9.0% and 8.0%, the decline in HbA~1c~ after 24 weeks is −1.85%, −1.36% and −0.87%, respectively, with empagliflozin 25 mg and −1.28%, −1.00% and −0.71%, respectively, with sitagliptin. Based on the results of Study 2, it can be predicted that for a starting HbA~1c~ of 10.0%, 9.0%, and 8.0%, the decline in HbA~1c~ after 52 weeks is −1.85%, −1.33% and −0.82%, respectively, with empagliflozin 25 mg and −1.35%, −1.03% and −0.71%, respectively, with glimepiride. In Study 2, the difference between the slopes for empagliflozin and glimepiride narrowed slightly and nonsignificantly at 104 weeks vs 52 weeks. Although this could reflect a waning of the effect of empagliflozin, we believe that this most likely represents a chance observation. Most importantly, this difference did not approach statistical significance. It also is possible that the small nonsignificant difference in the slope could be explained by the fact that urinary glucose excretion would be expected to decrease as the HbA~1c~ declined in the empagliflozin group. However, the reduction in HbA~1c~ was near maximal at 12 weeks and did not change thereafter.

The observation of greater reductions in HbA~1c~ with increasing baseline HbA~1c~ is consistent with the mechanism of action of SGLT2 inhibitors, which act by reducing the renal threshold for glucose spillage into the urine to values less than the normal fasting plasma glucose concentration.[9](#edm216-bib-0009){ref-type="ref"} SGLT2 inhibitors target glucose that would otherwise be reabsorbed by the kidney. Thus, it is expected that the higher the glucose concentration up till the (untreated) renal threshold for glucose, the greater the incremental excretion of glucose into the urine with SGLT2 inhibition, and, ultimately, the greater the expected decline in HbA~1c~. It should be noted that the reduction in HbA~1c~ observed with SGLT2 inhibitors is approximately 50% of that expected based on urinary glucose excretion, likely because of an increase in endogenous glucose production[17](#edm216-bib-0017){ref-type="ref"} and increased glucose reabsorption by SGLT1, which is capable of reabsorbing up to 30%‐40% of the filtered glucose load.[7](#edm216-bib-0007){ref-type="ref"} If the increase in endogenous glucose production were to be prevented or if glucose reabsorption by SGLT1 were blocked, the decline in HbA~1c~ for any given starting HbA~1c~ would potentially be even greater with empagliflozin compared to sitagliptin or glimepiride. Further, the slope of HbA~1c~ reduction in other commonly used antidiabetes agents will be influenced by their mechanism of action, that is, increased insulin secretion, glucagon suppression, inhibition of endogenous glucose production or insulin sensitization, which impose physiological limits to their efficacy. SGLT2 inhibitors reduce the renal threshold for glucose to well below the fasting plasma glucose concentration observed in individuals with normal glucose tolerance.[9](#edm216-bib-0009){ref-type="ref"} This may contribute to a disproportionately greater HbA~1c~ reduction with SGLT2 inhibitors than with other antidiabetes agents with increasing plasma glucose levels as long as GFR is not significantly reduced. Glycosuria with empagliflozin decreases with decreasing estimated GFR,[18](#edm216-bib-0018){ref-type="ref"} and in patients with type 2 diabetes who have a reduced GFR, the glucose‐lowering effect of empagliflozin is reduced.[19](#edm216-bib-0019){ref-type="ref"}

These are some limitations to the present analyses. First, these were post‐hoc analyses. Second, these exploratory analyses did not include the placebo arm of Study 1; this is different from the approach of the primary analysis of the study that included placebo as the main comparator.

In conclusion, reductions in HbA~1c~ with increasing baseline HbA~1c~ are greater with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.
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